Seelos Therapeutics (SEELQ) AI Stock Analysis

• Market Cap: $1.00
• Dividend Yield: N/A
• Average Volume (3M): 8.69K
• Price to Earnings (P/E): <0.1
• Beta (1Y): -0.35
• Revenue Growth: 76.05%
• EPS Growth: N/A
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): 176.64
• Shares Outstanding: 1,124,121
• 10 Day Avg. Volume: 2,464
• 30 Day Avg. Volume: 8,686
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 30 Underperform
• Price Target: ―

Seelos Therapeutics faces substantial financial and operational challenges, reflected in poor financial and technical scores. The low valuation score suggests potential undervaluation, but risks related to financial health and lack of guidance from the earnings call weigh heavily on the outlook.

Seelos Therapeutics Business Overview & Revenue Model

Company Description

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio include late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New York, NY.

How the Company Makes Money

Seelos Therapeutics generates revenue primarily through partnerships, collaborations, and potential licensing agreements related to its pharmaceutical development programs. As a clinical-stage company, it does not yet have products on the market, so its income depends significantly on securing funding from investors, grants, and strategic alliances with larger pharmaceutical companies. These partnerships could involve milestone payments, research funding, and future royalties based on successful commercialization of its drug candidates. The company may also raise capital through public or private offerings of its equity or debt securities to fund its ongoing research and development activities.

Seelos Therapeutics Financial Statement Overview

Summary

Seelos Therapeutics is facing significant financial challenges. Despite some revenue generation, the company operates at a loss with high operational costs. Negative stockholders' equity and cash flow issues highlight solvency risks and the need for financial restructuring.

Income Statement

Seelos Therapeutics has shown some revenue generation in 2023 with a gross profit margin of 100%. However, the company is still operating at a loss with a net profit margin of -171.98%, indicating high operational costs relative to its revenue. The EBIT and EBITDA margins are also deeply negative, reflecting ongoing challenges in achieving operational efficiency.

Balance Sheet

The balance sheet reveals significant financial strain with a negative stockholders' equity of -$33.48 million, indicating liabilities exceed assets. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, suggesting potential solvency issues.

Cash Flow

The cash flow analysis shows a negative free cash flow, consistent with past years, indicating ongoing cash outflows. The operating cash flow to net income ratio is slightly below 1, suggesting that cash outflows are closely mirroring net losses, which could be concerning for sustainability without new financing.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
―	―	―	―	―
	Gross Profit
2.20M	―	―	―	151.00K
	EBIT
-40.50M	-70.92M	-61.67M	-18.76M	-34.99M
	EBITDA
-37.75M	-73.47M	-64.45M	-18.94M	-51.23M
	Net Income Common Stockholders
-37.88M	-73.53M	-66.05M	-19.10M	-51.26M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
―	―	―	―	―
	Total Assets
5.42M	22.75M	83.50M	17.49M	11.10M
	Total Debt
14.23M	20.12M	18.96M	9.72M	0.00
	Net Debt
11.23M	4.59M	-59.78M	-5.94M	-10.26M
	Total Liabilities
38.93M	33.36M	26.18M	14.92M	11.10M
	Stockholders Equity
―	―	―	―	―
Cash Flow		Free Cash Flow
-23.91M	-61.60M	-48.99M	-20.91M	-19.30M
	Operating Cash Flow
-23.91M	-61.60M	-48.99M	-20.91M	-19.30M
	Investing Cash Flow
―	―	―	―	―
	Financing Cash Flow
―	―	―	―	―

Seelos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEELQ, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.37, and below the 200-day MA of 11.35, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 43.08 is Neutral, neither overbought nor oversold. The STOCH value of 25.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SEELQ.

Seelos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.24B	3.32	-44.36%	6.63%	16.78%	-0.12%
GRI	45 Neutral	$3.29M	―	-468.00%	―	―	98.55%
ONCO	33 Underperform	$2.09M	―	-237.69%	―	―	-97.16%
SEELQ	30 Underperform	$1.00	<0.01	113.13%	―	76.05%	―
SLRX	30 Underperform	$2.30M	―	-300.16%	―	―	79.57%
PCSA	29 Underperform	$2.88M	―	-192.72%	―	―	56.26%
QNRX	25 Underperform	$4.94M	―	-138.80%	―	―	42.26%